Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1,Condition 2,Condition 3a,Condition 3b 268,"Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.",body mass,,RS:0000742,WKY,female,360 days,4,,CMO:0000012,body weight,,,,200.8,g,3.45,6.9,MMO:0000016,body weighing method,,0,,,,,controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days),12589,controlled sodium content diet (0.4 %) (for 122 days),controlled sodium content diet (1.4 %) (for 210 days),, 268,"Inomata H, et al., Hypertens Res 2005 Mar;28(3):273-81.",body mass,,RS:0000742,WKY,male,360 days,4,,CMO:0000012,body weight,,,,318,g,6.65,13.3,MMO:0000016,body weighing method,,0,,,,,controlled sodium content diet (0.4 %) (for 122 days) then controlled sodium content diet (1.4 %) (for 210 days),12588,controlled sodium content diet (0.4 %) (for 122 days),controlled sodium content diet (1.4 %) (for 210 days),, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,16,,CMO:0000012,body weight,,,,261,g,7.0,28.0,MMO:0000016,body weighing method,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days),107448,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 136 days), 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,16,,CMO:0000012,body weight,,,,267,g,9.0,36.0,MMO:0000016,body weighing method,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 136 days) and bosentan (100 mg/kg/d) (for 136 days),107449,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 136 days),bosentan (100 mg/kg/d) (for 136 days) 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,11,,CMO:0000012,body weight,,,,408,g,10.0,33.1662,MMO:0000016,body weighing method,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then vehicle control condition,107445,unilateral nephrectomy (for 150 days),vehicle control condition,, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,17,,CMO:0000012,body weight,,,,274,g,6.0,24.7386,MMO:0000016,body weighing method,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 136 days),107447,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,bosentan (100 mg/kg/d) (for 136 days), 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,17,,CMO:0000012,body weight,,,,256,g,5.0,20.6155,MMO:0000016,body weighing method,,0.0,,unx,150,days,unilateral nephrectomy (for 150 days) then streptozotocin (35 mg/kg) then vehicle control condition,107446,unilateral nephrectomy (for 150 days),streptozotocin (35 mg/kg) ,vehicle control condition, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,6,,CMO:0000012,body weight,,,,229,g,6.0,14.6969,MMO:0000016,body weighing method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days),99939,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 14 days),bosentan (100 mg/kg/d) (for 14 days) 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,8,,CMO:0000012,body weight,,,,233,g,5.0,14.1421,MMO:0000016,body weighing method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days),99938,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,enalapril (10 mg/kg/d) (for 14 days), 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,8,,CMO:0000012,body weight,,,,236,g,7.0,19.799,MMO:0000016,body weighing method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days),99937,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,bosentan (100 mg/kg/d) (for 14 days), 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,8,,CMO:0000012,body weight,,,,215,g,10.0,28.2843,MMO:0000016,body weighing method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition,99936,unilateral nephrectomy (for 28 days),streptozotocin (35 mg/kg) ,vehicle control condition, 2378,"Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54.",body mass,,RS:0000742,WKY,male,0 days,7,,CMO:0000012,body weight,,,,268,g,13.0,34.3948,MMO:0000016,body weighing method,,0.0,,unx,28,days,unilateral nephrectomy (for 28 days) then vehicle control condition,99935,unilateral nephrectomy (for 28 days),vehicle control condition,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,10,,CMO:0000012,body weight,,,,241,g,5.0,15.8114,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100391,0.9% sodium chloride solution (3 ml) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,9,,CMO:0000012,body weight,,,,395,g,7.0,21.0,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,490,days,controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) ,100435,controlled enalapril content drinking water (50 mg/l) (for 497 days),puromycin aminonucleoside (50 mg/kg) ,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,8,,CMO:0000012,body weight,,,,418,g,15.0,42.4264,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,490,days,puromycin aminonucleoside (50 mg/kg) ,100434,puromycin aminonucleoside (50 mg/kg) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,9,,CMO:0000012,body weight,,,,412,g,6.0,18.0,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100433,0.9% sodium chloride solution (3 ml) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,8,,CMO:0000012,body weight,,,,305,g,6.0,16.9706,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100432,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),puromycin aminonucleoside (50 mg/kg) ,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,9,,CMO:0000012,body weight,,,,297,g,4.0,12.0,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100431,puromycin aminonucleoside (50 mg/kg) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,8,,CMO:0000012,body weight,,,,317,g,10.0,28.2843,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100430,0.9% sodium chloride solution (3 ml) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,5,,CMO:0000012,body weight,,,,245,g,12.0,26.8328,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,15,days,controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) ,100429,controlled enalapril content drinking water (50 mg/l) (for 22 days),puromycin aminonucleoside (50 mg/kg) ,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,7,,CMO:0000012,body weight,,,,245,g,9.0,23.8118,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100428,puromycin aminonucleoside (50 mg/kg) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,9,,CMO:0000012,body weight,,,,244,g,8.0,24.0,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100427,0.9% sodium chloride solution (3 ml) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,10,,CMO:0000012,body weight,,,,241,g,5.0,15.8114,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,15,days,controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) ,100393,controlled enalapril content drinking water (50 mg/l) (for 22 days),puromycin aminonucleoside (50 mg/kg) ,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,11,,CMO:0000012,body weight,,,,249,g,11.0,36.4829,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,15,days,puromycin aminonucleoside (50 mg/kg) ,100392,puromycin aminonucleoside (50 mg/kg) ,,, 2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",body mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000012,body weight,,,,286.6,g,21.95,69.412,MMO:0000016,body weighing method,,0.0,,,,days,streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) ,99112,streptozotocin (60 mg/kg) ,benazepril (10 mg/kg/d) ,gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) , 2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",body mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000012,body weight,,,,287.24,g,20.18,63.8148,MMO:0000016,body weighing method,,0.0,,,,days,streptozotocin (60 mg/kg) then benazepril (10 mg/kg/d) ,99111,streptozotocin (60 mg/kg) ,benazepril (10 mg/kg/d) ,, 2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",body mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000012,body weight,,,,295.56,g,21.89,69.2223,MMO:0000016,body weighing method,,0.0,,,,days,streptozotocin (60 mg/kg) then gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) ,99110,streptozotocin (60 mg/kg) ,gene transfer of the murine angiotensin I converting enzyme 2 gene using an adenovirus vector (40000000000 null) ,, 2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",body mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000012,body weight,,,,261.43,g,21.34,67.483,MMO:0000016,body weighing method,,0.0,,,,days,streptozotocin (60 mg/kg) then gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 null) ,99109,streptozotocin (60 mg/kg) ,gene transfer of the enhanced green fluorescent protein gene using an adenovirus vector (40000000000 null) ,, 2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",body mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000012,body weight,,,,259.65,g,18.96,59.9568,MMO:0000016,body weighing method,,0.0,,,,days,streptozotocin (60 mg/kg) ,99108,streptozotocin (60 mg/kg) ,,, 2219,"Liu CX, etal., Mol Med. 2011 Jan-Feb;17(1-2):59-69. doi: 10.2119/molmed.2010.00111. Epub 2010 Sep 14.",body mass,,RS:0000742,WKY,male,156 days,10,,CMO:0000012,body weight,,,,450.39,g,9.36,29.5989,MMO:0000016,body weighing method,,0.0,,,,days,vehicle control condition (1 null) ,99107,vehicle control condition (1 null) ,,, 2338,"Ohashi H, et al., Jpn Circ J. 1986 Feb;50(2):140-6.",body mass,,RS:0000742,WKY,male,245 days,7,,CMO:0000012,body weight,,,,373.6,g,11.1122,29.4,MMO:0000016,body weighing method,,0.0,,,,,naive control condition,99849,naive control condition,,, 2826,"Cerutti C, et al., Physiol Genomics. 2006 Nov 27;27(3):295-308. doi: 10.1152/physiolgenomics.00318.2005. Epub 2006 Aug 1.",body mass,,RS:0000742,WKY,male,84 days,5,,CMO:0000012,body weight,,,,260,g,7.0,15.6525,MMO:0000016,body weighing method,,0.0,,,,,naive control condition (for 0 hours),103476,naive control condition (for 0 hours),,, 2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",body mass,,RS:0000742,WKY,male,112 days,18,,CMO:0000012,body weight,,,,436,g,11.0,46.669,MMO:0000016,body weighing method,,0.0,,,,,in utero condition (30 % of calories) (for 22 days),99076,in utero condition (30 % of calories) (for 22 days),,, 2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",body mass,,RS:0000742,WKY,male,112 days,17,,CMO:0000012,body weight,,,,454,g,8.0,32.9848,MMO:0000016,body weighing method,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99075,controlled in utero environment (100 % of calories) (for 22 days),,, 2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",body mass,,RS:0000742,WKY,not specified,1 days,36,,CMO:0000012,body weight,,,,4.91,g,0.15,0.9,MMO:0000016,body weighing method,,0.0,,,,,in utero condition (30 % of calories) (for 22 days),99074,in utero condition (30 % of calories) (for 22 days),,, 2218,"Riviere G, et al., Hypertension. 2005 Nov;46(5):1169-74. Epub 2005 Oct 3.",body mass,,RS:0000742,WKY,not specified,1 days,26,,CMO:0000012,body weight,,,,6.64,g,0.14,0.7139,MMO:0000016,body weighing method,,0.0,,,,,controlled in utero environment (100 % of calories) (for 22 days),99073,controlled in utero environment (100 % of calories) (for 22 days),,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,280 days to 266 days,32,,CMO:0000012,body weight,,,,574,g,38.0,214.9605,MMO:0000016,body weighing method,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days) then ramipril (1 mg/kg/d) (for 182 days),100275,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),ramipril (1 mg/kg/d) (for 182 days), 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,280 days to 266 days,16,,CMO:0000012,body weight,,,,599,g,35.0,140.0,MMO:0000016,body weighing method,,0.0,,lad occlusion,210,days,left anterior descending coronary artery occlusion (for 224 days) then furosemide (10 mg/kg/d) (for 161 days),100274,left anterior descending coronary artery occlusion (for 224 days),furosemide (10 mg/kg/d) (for 161 days),, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,280 days to 266 days,5,,CMO:0000012,body weight,,,,562,g,22.0,49.1935,MMO:0000016,body weighing method,,0.0,,lad occlusion sham,210,days,sham surgical control condition (for 224 days),100273,sham surgical control condition (for 224 days),,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,252 days to 238 days,30,,CMO:0000012,body weight,,,,617,g,52.0,284.8157,MMO:0000016,body weighing method,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then vehicle control condition (for 182 days),100272,left anterior descending coronary artery occlusion (for 196 days),vehicle control condition (for 182 days),, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,252 days to 238 days,20,,CMO:0000012,body weight,,,,583,g,56.0,250.4396,MMO:0000016,body weighing method,,0.0,,lad occlusion,196,days,left anterior descending coronary artery occlusion (for 196 days) then furosemide (10 ml/kg/d) (for 182 days),100271,left anterior descending coronary artery occlusion (for 196 days),furosemide (10 ml/kg/d) (for 182 days),, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,252 days to 238 days,12,,CMO:0000012,body weight,,,,566,g,17.0,58.8897,MMO:0000016,body weighing method,,0.0,,lad occlusion sham,196,days,sham surgical control condition (for 196 days),100270,sham surgical control condition (for 196 days),,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,56 days to 42 days,30,,CMO:0000012,body weight,,,,225,g,1.8,9.859,MMO:0000016,body weighing method,,0.0,,lad occlusion,0,days,left anterior descending coronary artery occlusion then vehicle control condition,100269,left anterior descending coronary artery occlusion,vehicle control condition,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,56 days to 42 days,20,,CMO:0000012,body weight,,,,225,g,3.0,13.4164,MMO:0000016,body weighing method,,0.0,,lad occlusion,0,days,left anterior descending coronary artery occlusion then furosemide,100268,left anterior descending coronary artery occlusion,furosemide,, 2460,"Rokutan H, et al., Int J Cardiol. 2012 Sep 20;160(1):20-5. doi: 10.1016/j.ijcard.2011.03.005. Epub 2011 Mar 29.",body mass,,RS:0000742,WKY,male,56 days to 42 days,12,,CMO:0000012,body weight,,,,223,g,1.4,4.8497,MMO:0000016,body weighing method,,0.0,,lad occlusion,0,days,sham surgical control condition,100267,sham surgical control condition,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,12,,CMO:0000012,body weight,,,,312,g,4.0,13.8564,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,,,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days) then puromycin aminonucleoside (50 mg/kg) ,100396,controlled enalapril content drinking water (50 mg/l) (between 63 and 77 days),puromycin aminonucleoside (50 mg/kg) ,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,12,,CMO:0000012,body weight,,,,323,g,5.0,17.3205,MMO:0000016,body weighing method,,0.0,,PA IV 50mg/kg,,,puromycin aminonucleoside (50 mg/kg) ,100395,puromycin aminonucleoside (50 mg/kg) ,,, 2479,"Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68.",body mass,,RS:0000742,WKY,male,0 days,11,,CMO:0000012,body weight,,,,319,g,5.0,16.5831,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (3 ml) ,100394,0.9% sodium chloride solution (3 ml) ,,,